Thromboembolic Events Associated with Thalidomide and Multimodality Therapy for Soft Tissue Sarcomas: Results of RTOG 0330

<table>Treatment schema for RTOG 0330 cohort B. Neoadjuvant concurrent thalidomide (THAL) and radiation therapy (XRT) (stop THAL one week prior to surgery), followed by surgical resection, followed by adjuvant THAL for 6 months (post-op boost XRT if a positive margin).</table>

Sarcoma

fig2

Figure 2

Figure 2: Thromboembolic Events Associated with Thalidomide and Multimodality Therapy for Soft Tissue Sarcomas: Results of RTOG 0330 